mai President Prapan Charoenprawatt said that KLINIQ would list and start trading on mai in the Services industry group.
KLINIQ provides services on aesthetic dermatology, plastic surgery, and advanced preventive and holistic health rehabilitation in compliance with medical principles, consisting of skin disease treatment, cosmetic skin treatment, weight loss, body contouring, surgery, wellness and regeneration by a team of medical specialists in aesthetic and cosmetic surgery certified by well-known institutions in Thailand, the United States and the United Kingdom with experience in providing medical examination & treatment services in skin diseases and surgery equipped with advanced technology under the brand "The Klinique". As of June 30, 2022, the company has 39 branches in leading department stores, covering 15 provinces, all over five regions of Thailand. The 39 branches comprise 35 medical clinics, one surgical center at Siam Square in downtown Bangkok and three nail salons.
KLINIQ has a paid-up capital of THB 110 million, consisting of 160 million existing ordinary shares and 60 million newly issued shares, with a par value of THB 0.50 each. It offered up to 6 million newly issued shares to the company's directors, executives and employees, not over 9 million shares to the company's patrons, and at least 45 million shares to institutional investors and individuals at the underwriters' discretion, during October 28, 31, and November 1, at THB 24.50 each, for a total of THB 1.47 billion. The IPO price was equivalent to price-to-earnings ratio (P/E ratio) of 31.78 times. The earnings per share is equal to THB 0.77, which was calculated from the company's net profit of THB 169.60 million in the past four quarters (from July 1, 2021 to June 30, 2022), divided by fully diluted shares. Daol Securities (Thailand) pcl is the financial advisor and lead underwriter.
KLINIQ's Chief Executive Officer Apiruj Thongwattana, M.D. said that the company prioritizes safety and customer satisfaction, and always provides services with innovative and state-of-the-art medical equipment. It is a must to have the innovations and medical devices accredited and audited by the United States Food and Drug Administration (US FDA) and Thailand's FDA, and tested by the company's experienced medical team. The company has recorded continuous growth based on service enhancement and marketing tools to create awareness of 'The Klinique' brand. The fund raised will be used to expand business, purchase additional medical equipment, expand surgery center, develop IT systems & customer database, and as working capital.
KLINIQ's three major shareholders after the IPO are Thongwattana group (52.35 percent), Ekachai Medical Care pcl (7.27 percent), and Rattapol Kittichaitrakul (7.16 percent). The company's dividend policy is to pay no less than 40 percent of net profit from the company's separate financial statements after corporate income tax, and legal and other reserves.
For more information on KLINIQ, please see the company's prospectus at the Securities and Exchange Commission's website at www.sec.or.th; and for general information, please visit www.theklinique.com as well as www.set.or.th.
Source: SET Corporate Communications